A randomized controlled trial of transcatheter arterial chemoembolization(TACE) in patients with advanced hepatocellular:Comparison of periodical TACE versus recurrence time TACE

A randomized controlled trial of transcatheter arterial chemoembolization(TACE) in patients with advanced hepatocellular:Comparison of periodical TACE versus recurrence time TACE - Comparison of periodical TACE vs recurrence time TACE

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000690

Enrollment

Registered

2007-11-01

Start date

2007-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced hepatocellular carcinoma(HCC)

Interventions

TACE was underwent when the recurrence of HCC was observed via follow-up dynamic CT or MRI. However, when no recurrence of HCC was observed, planned periodic TACE was repeated at 6 month intervals.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: a)patients with untreated HCC not suitable for curative treatment b)Child A or B c)hypervascular tumor diagnosed via dynamic CT or MRI d)TNMStage 2-3 e) PS 0-2 f)serum creatinine level below 2mg/dl g)Age is within 20-79 years old

Exclusion criteria

Exclusion criteria: a)patients with HCC suitable for curative treatment b)Child C c)allergy of contrast medium d)list of living donor liver transplantation e)portal vein tumor thrombus f)extrahepatic metastasis g)sponteneous tumor rupture h)The patients whom judged to be inadequate by clinical trial liability or clinical trial allotment doctor.

Design outcomes

Primary

Measure	Time frame
cumulative survival rate	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026